denileukin difitox (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

Cutaneous T-Cell Lymphoma

Reformulated product pending FDA approval for treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL)

Next:

Pharmacology

Mechanism of Action

Recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments; specifically binds to IL-2 receptors on cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.